Navigation Links
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. Arena is finishing a complete analysis of the data, but does not anticipate any further development of APD125.

"While we are disappointed and anticipated a different result based on objective polysomnographic results from our previous studies, our priority remains the successful development of lorcaserin, our proprietary investigative treatment for obesity. We expect to announce lorcaserin results from BLOOM, our first pivotal Phase 3 clinical trial, around the end of March and to file a New Drug Application for lorcaserin by the end of 2009," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the opportunity to review our lorcaserin program, as well as other programs, at our upcoming R&D Day on December 15."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Critical Pharmaceuticals Enter Sustained Release hGH Arena
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
8. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Hedgeye Risk Management Healthcare team, led by Tom Tobin, will host ... Demographics of Demand and Profits in Healthcare," where we will be ... 1994-2002 was so good, and why the next decade looks so ... for hip, knee, and spine device growth. -   ...
... Oct. 6 Pharmaceutical and biotech companies reach much ... partnerships between R&D and marketing, balancing therapeutic innovation with ... requires companies to break down the walls that have ... strengths of both talented medical researchers and skillful marketers. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Creating Partnerships Across R&D and Marketing to Ensure a Successful Global Launch 2
(Date:8/29/2014)... Honey Gifts, premium Vancouver adult toys ... be selling purse-sized adult toys and erotic products. These ... can be carried in a woman’s purse with complete ... at Honey Gifts is also leak-free and will not ... batteries are common characteristics of Honey Gifts’ portable toys ...
(Date:8/29/2014)... Ore. (PRWEB) August 29, 2014 University ... of health sciences professionals, announced that Daniel Redwood, DC, ... was named “Educator of the Year,” by the Missouri ... banquet on August 21. , Patrick Montgomery, DC, president ... appointed member of the Missouri House Task Force for ...
(Date:8/29/2014)... August 29, 2014 The ... revenue growth over the five years to 2014 ... consumers had less disposable income and, consequently, reduced ... visited restaurants less frequently. As a result, demand ... hindering revenue growth. “After 2010, levels of household ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The West African Ebola ... Health Organization announcing an estimated 500 new cases this week ... of the new cases arose in Liberia, the U.N. health ... rose sharply, the Associated Press reported. "There ... control," according to the WHO report. "The situation is worsening ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Evolutions ... Santa Barbara in the Santa Barbara News-Press Readers’ Choice ... won the Readers’ Choice poll as Best Medical Spa. ... 2014 reads the following about Evolutions Medical Spa recognition: ... but it is recognized as a top-notch, cutting-edge medical ...
Breaking Medicine News(10 mins):Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2Health News:Fruit and Vegetable Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fruit and Vegetable Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 3Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3
... March 22 (HealthDay News) -- New research suggests that middle-age ... less likely to suffer from heart disease over their lives. ... high-fiber diets to lower rates of high blood pressure, obesity ... to the conclusion after studying the results of a 2003-2008 ...
... to be female, suffer from a neurological or mental disorder, ... in the March issue of the Journal of the ... alcohol abuse by the perpetrator plays a substantial role and ... professor of environmental and occupational health sciences at the University ...
... To help continue its internationally recognized work in Lewy ... awarded Mayo Clinic a $1 million gift, pledged over four ... Alzheimer,s and Parkinson,s diseases , is the second ... VIDEO ALERT: Additional audio and video resources, including ...
... 22 (HealthDay News) -- A low-cost screening test detected potentially ... children and teens in a pilot study. The findings ... for heart conditions that can lead to sudden cardiac arrest ... said in a hospital news release. Researchers found that ...
... (March 22, 2011) When physical therapy and drugs fail to ... fusion surgery as a last resort, but two new studies ... involved, artificial disc replacement may give better long-term results at ... 49 percent lower, and four years out from surgery, artificial ...
... Salamon HealthDay Reporter , MONDAY, March 21 ... presumably have more opportunities for tanning -- are nearly ... cancer melanoma as their poorest counterparts, a new study ... incidence, ultraviolet (UV) light exposure and socioeconomic status, scientists ...
Cached Medicine News:Health News:Elderly victims of abuse often use alcohol or drugs, study says 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 3Health News:Screening Seems to Catch Dangerous Heart Condition in Kids 2Health News:For back, neck pain, artificial disc replacement has cost, outcome advantages over fusion surgery 2Health News:For back, neck pain, artificial disc replacement has cost, outcome advantages over fusion surgery 3Health News:Richer White Women More Prone to Melanoma, Study Finds 2Health News:Richer White Women More Prone to Melanoma, Study Finds 3
Designed to minimize emblolic debris in SVGs and carotids...
... therapy extends the ability of interventional ... coronary artery disease, and provides non-interventional ... in the treatment of patients who ... EECP therapy provides a noninvasive, atraumatic ...
... The dual lumen petite titanium ... mm catheter (each lumen) and ... oval lumen catheters offer larger ... catheter strength. Dual lumen offset-tip ...
... The dual lumen M.R.I. model ... 1.2 mm inner diameter catheters ... catheters offer larger lumen equivalency ... ,Dual lumen offset-tip catheters are ...
Medicine Products: